The Antibody Solution
ArkAb products are based on B Cell Design platform which is a patented transgenic mouse model generated in an academic laboratory (UMR CNRS 7276 - Limoges University - CRIBL – “B cells immune response control and lymphoproliferation”, directed by Pr. Dr. Michel Cogné).
B Cell Design has the exclusive licenses for the three mice models: HAMIGA™ GammaPrim™ and InEps™ for which B Cell Design is the co-owner of the patent.
The insertion of a human cassette carrying the gene of the immunoglobulin heavy chain constant region in the endogenous locus leads to the expression of human chimeric antibodies directly by the mouse lymphocytes. Therefore, these mice are secreting antibodies with the following properties:
- only one human isotype per mouse line
- the heavy chain constant region is human
- the variable regions are from the mouse
- the mouse's complete immune repertoire is maintained
There are 3 mice lines producing human IgA1, IgG1 and IgM and IgE respectively:
| Mouse line | Antibody produced |
|---|---|
| HAMIGA™ | Chimeric human/mouse IgA1 |
| GammaPrim™ | Chimeric human/mouse IgG1 |
| InEps™ | Chimeric human/mouse IgM and IgE by an in vitro induced class switching |
Mouse model descriptions
HAMIGA™ - IgA1
Specifications:
- Isotype: IgA1
- Applications fields: research, therapeutic, in vitro diagnosis (infectious diseases, autoimmunity)
- Possible functions: neutralization (therapeutic), cytotoxicity (therapeutic), in vivo medical imaging, calibrator, quality control, positive control
Innovations:
- 60% of B Cells are producing IgA1 (vs 1% in wild-type animals)
- High specificity and high in vitro titer
- Human chimeric antibodies (carrying a human heavy chain constant region)
- The mouse repertoire architecture is maintained: the ability to target all kinds of antigens is intact
- High level of clone generation efficacy, ensuring higher probability of selecting the monoclonal antibody of interest.
Patent : « Mammifère non humain transgénique pour la région constante de la chaîne lourde des immunoglobulines humaines de classe A et ses applications » Cogné M., Sirac C., Bardel M., Decourts C. et Le Morvan C. N°04805265.8 du 21/10/04
GammaPrim™ - IgG1
Specifications:
- Isotype: IgG1
- Applications fields: therapeutic, in vitro diagnosis (infectious diseases, autoimmunity)
- Possible functions: Immunotherapy, R&D, drug candidates , companion diagnosis, Diagnostic calibrator, quality control, positive control
Innovations:
- 99% of hybridomas produce IgG1
- High specificity and high-titer in vitro
- Human chimeric antibodies (carrying a human heavy chain constant region)
- The Mouse repertoire architecture is maintained: the ability to target all kinds of antigens is intact
- High level of clone generation efficacy, ensuring higher probability of selecting the monoclonal antibody of interest.
- Same range of affinity as natural human IgG1 (demonstrated by a competitiveness test)
Patent : « Souris transgéniques pour le gène Gamma des immunoglobulines humaines de classe G » Cogné M., Duchez S., Cogné N., Pinaud E. European patent N°04805265.8 of 22/01/2009.
InEps™ - IgM and IgE
Specifications:
- Isotype: IgM and IgE
- Applications fields: research, in vitro diagnosis (infectious diseases, allergy)
- Possible functions: In vitro diagnostic calibrator, quality control, positive control, immunoassay/immunocapture pair
Innovations:
- B Cells produce IgM and after in vitro class switching, B Cells produce IgE
- Long term production of reproducible lots of specific IgM
- Only sustainable production process for specific monoclonal IgE
- High affinity
- High specificity and high-titer in vitro
- Human chimeric antibodies (carrying a human heavy chain constant region)
- The Mouse repertoire architecture is maintained: the ability to target all kinds of antigens is intact
- High level of clone generation efficacy, ensuring higher probability of selecting the monoclonal antibody of interest.
Patent : « Transgenic non-human mammal for producing chimeric human immunoglobulin E antibodies » Cogné M., Laffleur, B., Cuvillier A. (B Cell Design) et Bosselut M. (B Cell Design) European patent N°13305964.2 of 05/07/2013.